FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081849522> ?p ?o ?g. }

• W3081849522 abstract "Background: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19infection in the United Kingdom from November 2020 with a transmission advantage over the previous variants of the virus. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant in comparison with non-B.1.1.7 lineages.Methods: Volunteers enrolled in phase II/III vaccine efficacy studies in the United Kingdom and randomised 1:1 to receive ChAdOx1 nCoV-19 or a MenACWY control vaccine, providedupper airway swabs every week during the trial and also if they developed possible symptomatic COVID-19 infection. Swabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2, and positive samples were sequenced through the COVID-19Genomics UK consortium (COG UK). NAAT data were used to assess the duration ofdetectable viral RNA in diagnostic specimens and the viral load. Anti-spike IgG wasmeasured by ELISA at baseline, 14 and 28 days after prime and 28 days after boostervaccination. Neutralising antibody responses were measured using a live virus neutralisation assay against the B.1.1.7 and Victoria lineages of the virus. The efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cut-off on Jan 14, 2021. Vaccine efficacy was calculated as 1 − relative risk derived from a robust Poisson regression model. This study is ongoing and is registered with ClinicalTrials.gov NCT04400838 and ISRCTN 15281137.5Findings: Between 1st October 2020 and 14th January 2021, 499 participants developed Covid-19infection. 1524 NAAT positive nose/throat swabs were collected from these participants during the trial. Of these, 323 swabs from 256 participants were successfully sequenced.ChAdOx1 nCoV-19 recipients had a significantly lower viral load as represented byminimum PCR Ct value (p<0.0001) and were NAAT positive for a shorter time (p<0.0001) than participants who received the control vaccine. Virus neutralisation activity by vaccineinduced antibodies was 9-fold lower against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection was similar for B.1.1.7 and non-B1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). There was no difference in anti-spike antibody titres between individuals who had received a prior ChAdOx1 vectored vaccine and those who were naive to ChAdOx1.Interpretation: Efficacy of ChAdOx1 nCoV-19 against the B.1.1.7 variant of SARS-CoV-2 is similar to the efficacy of the vaccine against other lineages. Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease.Trial Registration Number: This study is ongoing and is registered with ClinicalTrials.gov NCT04400838 and ISRCTN 15281137.Funding: The clinical trial was funded by UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR OxfordBiomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome SangerInstitute. Computational work was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC.Conflict of Interest: Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. AstraZeneca reviewed the data from the study and the final manuscript before submission, but the authors retained editorial control. SCG is cofounder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines (PCT/GB2012/000467) and a patent application covering this SARS-CoV-2 vaccine. TL is named as an inventor on a patentapplication covering this SARS-CoV-2 vaccine and was consultant to Vaccitech. PMF is a consultant to Vaccitech. AJP is Chair of the UK Department of Health and Social Care’s JCVI, but does not participate in policy advice on coronavirus vaccines, and is a member of the WHO Strategic Advisory Group of Experts (SAGE). AJP and SNF are NIHR SeniorInvestigators. AVSH is a cofounder of and consultant to Vaccitech and is named as aninventor on a patent covering design and use of ChAdOx1-vectored vaccines(PCT/GB2012/000467). MDS reports grants from Janssen, GlaxoSmithKline, Medimmune,Novavax, and MCM Vaccine and grants and non-financial support from Pfizer outside of the submitted work. CG reports personal fees from the Duke Human Vaccine Institute outside of the submitted work. ADD reports grants and personal fees from AstraZeneca outside of the submitted work. SNF reports grants from Janssen and Valneva, outside the submitted work.TLV and JV are employees of AstraZeneca. All other authors declare no competing interests.The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.Ethical Approval: The study was sponsored by the University of Oxford (Oxford, UK) and approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) reference 21584/0428/001-0001 and the South-Central Berkshire Research Ethics Committee reference 20/SC/0179." @default.
• W3081849522 created "2020-09-08" @default.
• W3081849522 creator A5000539122 @default.
• W3081849522 creator A5000717053 @default.
• W3081849522 creator A5000793343 @default.
• W3081849522 creator A5001065613 @default.
• W3081849522 creator A5001510635 @default.
• W3081849522 creator A5005979486 @default.
• W3081849522 creator A5007933241 @default.
• W3081849522 creator A5008728042 @default.
• W3081849522 creator A5015357500 @default.
• W3081849522 creator A5015402059 @default.
• W3081849522 creator A5016043829 @default.
• W3081849522 creator A5017470287 @default.
• W3081849522 creator A5021492528 @default.
• W3081849522 creator A5023735316 @default.
• W3081849522 creator A5023979478 @default.
• W3081849522 creator A5024795242 @default.
• W3081849522 creator A5025008078 @default.
• W3081849522 creator A5025936000 @default.
• W3081849522 creator A5027283905 @default.
• W3081849522 creator A5027722435 @default.
• W3081849522 creator A5028821098 @default.
• W3081849522 creator A5032068223 @default.
• W3081849522 creator A5033629213 @default.
• W3081849522 creator A5033735799 @default.
• W3081849522 creator A5034393834 @default.
• W3081849522 creator A5035322549 @default.
• W3081849522 creator A5037138357 @default.
• W3081849522 creator A5037611686 @default.
• W3081849522 creator A5038939804 @default.
• W3081849522 creator A5040051815 @default.
• W3081849522 creator A5040443453 @default.
• W3081849522 creator A5043115626 @default.
• W3081849522 creator A5043689591 @default.
• W3081849522 creator A5046531377 @default.
• W3081849522 creator A5046673368 @default.
• W3081849522 creator A5047085385 @default.
• W3081849522 creator A5050591423 @default.
• W3081849522 creator A5051476386 @default.
• W3081849522 creator A5052777019 @default.
• W3081849522 creator A5055232452 @default.
• W3081849522 creator A5057807377 @default.
• W3081849522 creator A5059374302 @default.
• W3081849522 creator A5061392488 @default.
• W3081849522 creator A5064651300 @default.
• W3081849522 creator A5065466737 @default.
• W3081849522 creator A5065859245 @default.
• W3081849522 creator A5065914659 @default.
• W3081849522 creator A5067020030 @default.
• W3081849522 creator A5067034561 @default.
• W3081849522 creator A5067773219 @default.
• W3081849522 creator A5071911197 @default.
• W3081849522 creator A5073128317 @default.
• W3081849522 creator A5073684725 @default.
• W3081849522 creator A5077123406 @default.
• W3081849522 creator A5077353929 @default.
• W3081849522 creator A5079855257 @default.
• W3081849522 creator A5081368739 @default.
• W3081849522 creator A5082525047 @default.
• W3081849522 creator A5082847955 @default.
• W3081849522 creator A5083880965 @default.
• W3081849522 creator A5087255374 @default.
• W3081849522 creator A5088009800 @default.
• W3081849522 creator A5088973528 @default.
• W3081849522 creator A5089550105 @default.
• W3081849522 creator A5090057576 @default.
• W3081849522 creator A5091048034 @default.
• W3081849522 date "2021-01-01" @default.
• W3081849522 modified "2023-09-28" @default.
• W3081849522 title "Efficacy of ChAdOx1 nCoV-19&nbsp;(AZD1222)&nbsp;Vaccine Against SARS-CoV-2 VOC&nbsp;202012/01&nbsp;(B.1.1.7)" @default.
• W3081849522 doi "https://doi.org/10.2139/ssrn.3779160" @default.
• W3081849522 hasPublicationYear "2021" @default.
• W3081849522 type Work @default.
• W3081849522 sameAs 3081849522 @default.
• W3081849522 citedByCount "34" @default.
• W3081849522 countsByYear W30818495222021 @default.
• W3081849522 countsByYear W30818495222022 @default.
• W3081849522 crossrefType "journal-article" @default.
• W3081849522 hasAuthorship W3081849522A5000539122 @default.
• W3081849522 hasAuthorship W3081849522A5000717053 @default.
• W3081849522 hasAuthorship W3081849522A5000793343 @default.
• W3081849522 hasAuthorship W3081849522A5001065613 @default.
• W3081849522 hasAuthorship W3081849522A5001510635 @default.
• W3081849522 hasAuthorship W3081849522A5005979486 @default.
• W3081849522 hasAuthorship W3081849522A5007933241 @default.
• W3081849522 hasAuthorship W3081849522A5008728042 @default.
• W3081849522 hasAuthorship W3081849522A5015357500 @default.
• W3081849522 hasAuthorship W3081849522A5015402059 @default.
• W3081849522 hasAuthorship W3081849522A5016043829 @default.
• W3081849522 hasAuthorship W3081849522A5017470287 @default.
• W3081849522 hasAuthorship W3081849522A5021492528 @default.
• W3081849522 hasAuthorship W3081849522A5023735316 @default.
• W3081849522 hasAuthorship W3081849522A5023979478 @default.
• W3081849522 hasAuthorship W3081849522A5024795242 @default.
• W3081849522 hasAuthorship W3081849522A5025008078 @default.
• W3081849522 hasAuthorship W3081849522A5025936000 @default.
• W3081849522 hasAuthorship W3081849522A5027283905 @default.
• W3081849522 hasAuthorship W3081849522A5027722435 @default.
• W3081849522 hasAuthorship W3081849522A5028821098 @default.

• next